夜間頻尿とは、夜間に2回以上排尿がある状態をいいます。夜間頻尿は、年齢が上がるにつれて多くなり、男女ともに起こりますが、時には異なる理由で起こることもあります。夜間頻尿の原因としては、うっ血性心不全、下肢の浮腫、閉塞性睡眠時無呼吸症候群などの睡眠障害、利尿剤、心臓配糖体、デメクロサイクリン、リチウム、メトキシフルラン、フェニトイン、プロポキシフェン、ビタミンD過剰摂取などの特定の薬剤、就寝前の水分摂取、特にコーヒー、カフェイン飲料、アルコールなどの過剰摂取などがあげられます。治療には抗コリン薬が使用されます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nocturia - Overview
Nocturia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nocturia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nocturia - Companies Involved in Therapeutics Development
Ferring International Center SA
Ferring Research Institute Inc
Tacurion Pharma Inc
Wellesley Pharmaceuticals LLC
Nocturia - Drug Profiles
(acetaminophen + ibuprofen) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASP-7035 - Drug Profile
Product Description
Mechanism Of Action
History of Events
desmopressin acetate ODT - Drug Profile
Product Description
Mechanism Of Action
History of Events
FE-201836 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide 1 to Agonise Vasopressin V2 Receptor for Nocturia - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Agonise Vasopressin V2 Receptor for Nocturia - Drug Profile
Product Description
Mechanism Of Action
Nocturia - Dormant Projects
Nocturia - Discontinued Products
Nocturia - Product Development Milestones
Featured News & Press Releases
Nov 09, 2018: NOCDURNA (desmopressin acetate) sublingual tablets now available by prescription in US for treatment of nocturia due to nocturnal polyuria
Aug 08, 2017: Ferring Pharmaceuticals: The Scottish Medicines Consortium Approves Use of NOQDIRNA (oral lyophilisate desmopressin), the First Licensed Treatment for Nocturia due to Idiopathic Nocturnal Polyuria in Adults
Aug 07, 2017: Noqdirna is accepted for restricted use within NHS Scotland
Feb 13, 2017: Scottish Medicines Consortium Rejects Noqdirna For Use Within NHS Scotland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Nocturia, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Nocturia - Pipeline by Ferring International Center SA, 2022
Nocturia - Pipeline by Ferring Research Institute Inc, 2022
Nocturia - Pipeline by Tacurion Pharma Inc, 2022
Nocturia - Pipeline by Wellesley Pharmaceuticals LLC, 2022
Nocturia - Dormant Projects, 2022
Nocturia - Discontinued Products, 2022
List of Figures
Number of Products under Development for Nocturia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
